{"id":"nct:NCT03217617","kind":"trial","title":"SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection","authors":["Shenzhen Geno-Immune Medical Institute"],"author_count":1,"year":2017,"published":"2017-07-14","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT03217617","source_url":"https://clinicaltrials.gov/study/NCT03217617","archive_url":"https://space-kitty.com/papers/nct:NCT03217617","updated":"2026-08-27","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intravenous lentiviral gene transfer protocol.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["SCID, X-Linked"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"sponsor":"Shenzhen Geno-Immune Medical Institute","conditions":["SCID, X-Linked"],"interventions":["BIOLOGICAL: Direct intravenous injection of ivlv-X1 lentiviral vector"],"start_date":"2027-06-30","start_date_type":"ESTIMATED","primary_completion_date":"2028-12-31","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}